Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Isentress Approval Carries Limited Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA follows lead of its September Antiviral Drugs Advisory Committee recommendation.
Advertisement

Related Content

Tivicay Launch Returns ViiV To HIV Spotlight And Growth
ViiV Secures Its First New Drug Approval With Tivicay
HIV Drug Project Would Aim For A Cure
HIV Drug Project Would Aim For A Cure
AIDS Drug Assistance Programs Quickly Added Merck’s Isentress, Pfizer’s Selzentry, Despite Coverage Grace Period
AIDS Drug Assistance Programs Quickly Added Merck’s Isentress, Pfizer’s Selzentry, Despite Coverage Grace Period
Merck, NIH Cannot Explain Higher Number Of AIDS Cases In HIV Vaccinated Individuals
Gardasil Gains Blockbuster Status In Its First Year On The Market
Isentress Gets Unanimous Nod From Advisory Committee, But May Get Limited Indication
Isentress Gets Unanimous Nod From Advisory Committee, But May Get Limited Indication

Topics

Advertisement
UsernamePublicRestriction

Register

PS065182

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel